SEELOS THERAPEUTICS, INC.
SEELOS THERAPEUTICS, INC. (SEEL): 6 pipeline candidates · ~3 mo cash runway · 2 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
2.8 months
D/E -1.08 · 0% dilution
Lead: Phase 2/Phase 3
6 candidates
N/A
N/A
A transparent, data-derived signal for SEELOS THERAPEUTICS, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$294K
Quarterly Burn
$972K
Runway
2.8 mo
Revenue
$376K
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (6 candidates)
Frequently asked questions
How many drug candidates are in SEELOS THERAPEUTICS, INC.'s pipeline?
SEELOS THERAPEUTICS, INC. (SEEL) has 6 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is SEELOS THERAPEUTICS, INC.'s lead drug candidate?
SEELOS THERAPEUTICS, INC.'s most advanced tracked candidate is sls-002 (Phase 2) for Acute Suicidal Ideation and Behavior ("ASIB") in Major Depressive Disorder ("MDD").
What is SEELOS THERAPEUTICS, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, SEELOS THERAPEUTICS, INC. has approximately 2.8 months of cash runway.
Who is the CEO of SEELOS THERAPEUTICS, INC.?
Raj Mehra, Ph.D. is the chief executive officer of SEELOS THERAPEUTICS, INC. (SEEL).
Get the full picture on SEELOS THERAPEUTICS, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.